40K glycoPEGylated, recombinant FVIIa: 3-month, double-blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors - Ljung, R; Karim, F A; Saxena, K (J Thromb Haemost, 2013)
, et al; Pioneer™1 Investigators.